STOCK TITAN

Fortress Biotech (FBIO) SEC Filings

FBIO NASDAQ

Fortress Biotech, Inc. filings document a biopharmaceutical issuer with common stock and 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock listed on the Nasdaq Capital Market. Its SEC record includes Form 8-K reports on operating results, FDA approvals, priority review voucher monetization, credit agreement amendments and subsidiary capital actions.

Proxy materials describe annual meeting matters, board governance, executive compensation and equity awards. Registration statements and material-event filings add disclosure on securities offerings, capital structure, risk factors, material agreements and ownership interests in portfolio companies such as Cyprium Therapeutics and Journey Medical.

Rhea-AI Summary

Fortress Biotech (FBIO) reported net revenue of $19.159 million for the quarter ended September 30, 2026, versus $17.631 million a year earlier. Net loss attributable to common stockholders was $7.853 million, compared with net income of $3.675 million; operating loss was $7.193 million, versus $6.811 million.

For the first nine months of 2026, net income attributable to Fortress was $104.060 million, compared with $10.752 million in 2025. The 2026 period included a $158.873 million gain from the sale of a priority review voucher. Net cash provided by operating activities was $138.377 million, compared with $53.233 million used in 2025.

Cash and cash equivalents were $152.186 million as of September 30, 2026; cash and cash equivalents of $114.1 million for Fortress and private subsidiaries primarily funded by Fortress were considered sufficient for their operations for at least 12 months following the report’s filing. Fortress paid Oaktree $15.6 million on September 30, terminating the $50.0 million senior secured credit agreement. Its subsidiary AcqCorpLXII obtained an exclusive worldwide license for FB-607, with up to $25.0 million in development and regulatory milestones and up to $35.0 million in commercial milestones payable to the licensor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.53%
Tags
quarterly report
-
Rhea-AI Summary

Fortress Biotech, Inc. reported third-quarter 2026 net revenue of $19.159 million, up approximately 9% from $17.631 million a year earlier. Net loss attributable to common stockholders was $7.853 million, versus net income of $3.675 million in the third quarter of 2025. For the nine months ended September 30, 2026, net income attributable to common stockholders was $98.036 million; that period included a $158.873 million gain on sale of a priority review voucher, net of expenses. Cash and cash equivalents were $152.186 million as of September 30, 2026, compared with $79.381 million as of December 31, 2025.

Fortress repaid its credit facility with Oaktree in full in September 2026. A subsidiary entered into a license agreement for FB-607, which is in a Phase 2 study for irritable bowel syndrome with diarrhea; top-line data are expected in the second half of 2027. Anselamimab (formerly CAEL-101) was approved in Japan in September for systemic kappa light chain amyloidosis. Emrosi had approximately 40,000 total prescriptions in the quarter, while Crystalys Therapeutics closed a $130 million Series B financing; royalties were generated from ZYCUBO and UNLOXCYT.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.53%
Tags
current report
-
Rhea-AI Summary

Fortress Biotech, Inc. (FBIO) is the subject of amended ownership disclosures listing Integrated Core Strategies (US) LLC with beneficial ownership of 2,165,122 shares, and Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander with 2,165,401 shares each. Each cover page reports 6.5% of the class and shared voting and dispositive power, with zero sole voting or dispositive power.

The ownership statement says securities potentially attributed to Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC and Israel A. Englander. It states that this disclosure alone is not an admission of beneficial ownership by those parties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.00%
Tags
ownership
Rhea-AI Summary

Fortress Biotech, Inc. (FBIO) repaid in full the remaining $15.0 million in principal under its Oaktree Agreement on September 30, 2026. It also paid approximately $435,000 in accrued interest, a $150,000 prepayment fee and other closing costs.

Following repayment, all indebtedness under the agreement was satisfied and paid in full, all liens and other security interests securing it were released and terminated, and the agreement automatically terminated pursuant to its terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
current report
-
Rhea-AI Summary

Fortress Biotech, Inc. Chief Financial Officer David Jin acquired 1,190 shares of common stock at $1.819 per share on October 1, 2026, under the company's Employee Stock Purchase Plan. The acquisition was voluntarily reported and was exempt under Rule 16b-3(d) and Rule 16b-3(c); no Rule 10b5-1 plan is reported. His reported holdings after the acquisition were 1,652,761 shares, including 1,230,000 shares underlying deferred restricted stock units and 400,000 shares underlying restricted stock units.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
insider
-
Rhea-AI Summary

Fortress Biotech, Inc. (FBIO) is the subject of a Schedule 13G filed by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reporting passive beneficial ownership of Fortress Biotech common stock. The reporting group discloses beneficial ownership of up to 1,778,561 shares of common stock, representing 5.3% of the class, held with shared voting and dispositive power and no sole voting or dispositive power. The filing states that the securities are held by entities over which Millennium Management LLC and related entities have voting control and investment discretion, and it notes that this structure should not itself be construed as an admission of beneficial ownership by Millennium Management LLC, Millennium Group Management LLC, or Mr. Englander.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
ownership
Rhea-AI Summary

Fortress Biotech, Inc. reported consolidated net income of $137.8 million for the six months ended June 30, 2026, driven primarily by a $158.9 million gain on the sale of a Rare Pediatric Disease priority review voucher at subsidiary Cyprium. Net revenue for the period was $34.8 million, while total operating expenses of $52.5 million produced a loss from operations of $17.7 million, indicating that core operations remain unprofitable.

Cash and cash equivalents rose to $196.6 million at June 30, 2026 from $79.4 million at year-end 2025, supported by $144.6 million of net cash provided by operating activities. Total assets increased to $316.7 million, and total stockholders’ equity to $206.1 million, partly reflecting the Cyprium dividend and fair value gains on equity investments. Notes payable, net, declined to $39.6 million, and the company was in compliance with covenants under both the Oaktree and SWK credit facilities.

Management states that $153.8 million of cash and cash equivalents at the parent entity level is considered sufficient to fund operations for at least twelve months after the report date, though additional capital may be needed for development programs and strategic growth. Dividends on the 9.375% Series A preferred stock remain paused and cumulative undeclared dividends totaled about $16.0 million as of June 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
quarterly report
-
Rhea-AI Summary

Fortress Biotech, Inc. reported second-quarter 2026 net revenue of $18.7 million, a 14% increase over the same quarter in 2025. Product revenue reached $17.8 million, and total net revenue for the first six months of 2026 was $34.8 million, up from $29.6 million a year earlier.

Despite higher revenue, the quarter showed a net loss attributable to common stockholders of $2.5 million, compared with net income of $13.4 million in the prior-year quarter. For the first half of 2026, net income attributable to common stockholders was $105.9 million, driven largely by a $158.9 million gain from the sale of a priority review voucher and other investment-related items.

The balance sheet strengthened notably: cash and cash equivalents were $196.6 million as of June 30, 2026, up from $79.4 million at year-end 2025. Total assets rose to $316.7 million, while long-term notes payable declined to $34.6 million. Total stockholders’ equity increased to $206.1 million, from $62.2 million at December 31, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
current report
-
Rhea-AI Summary

Jin David reported acquisition or exercise transactions in this Form 4 filing.

Fortress Biotech, Inc. Chief Financial Officer Jin David reported receiving an equity compensation grant of 400,000 restricted stock units, each representing one share of common stock. The units vest in four equal annual installments, with the first vesting on January 5, 2027, contingent on his continued service.

After this award, his reported holdings total 1,651,571 shares of common stock, including 1,230,000 shares underlying previously granted deferred restricted stock units. The transaction reflects a grant or award, not an open-market purchase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
insider
Rhea-AI Summary

Fortress Biotech reported the results of its 2026 annual meeting of stockholders held virtually on June 17. Stockholders voted on electing seven directors to serve until the 2027 meeting and on ratifying KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.

Each director nominee, including Lindsay A. Rosenwald, Jimmie Harvey Jr., Malcolm Hoenlein, Dov Klein, J. Jay Lobell, Kevin L. Lorenz, and Michael S. Weiss, received more votes "For" than "Against." The proposal to ratify KPMG LLP also received substantially more votes "For" than "Against," based on the reported vote totals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
current report

FAQ

How many Fortress Biotech (FBIO) SEC filings are available on StockTitan?

StockTitan tracks 34 SEC filings for Fortress Biotech (FBIO), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Fortress Biotech (FBIO)?

The most recent SEC filing for Fortress Biotech (FBIO) was filed on November 13, 2026.